{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:35:53Z","timestamp":1793111753675,"version":"4.5.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"The study was funded by Amgen Inc. (Thousand Oaks, CA, USA)."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine reversion rates from chronic migraine to episodic migraine during long-term erenumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A daily headache diary was completed during the 12-week, double-blind treatment phase of a placebo-controlled trial comparing erenumab 70\u2009mg, 140\u2009mg, and placebo, and weeks 1\u201312, 21\u201324, 37\u201340, and 49\u201352 of the open-label treatment phase. Chronic migraine to episodic migraine reversion rates were assessed over the double-blind treatment phase;\n                      <jats:italic>persistent reversion<\/jats:italic>\n                      to episodic migraine over 24 weeks (double-blind treatment phase through the first 12 weeks in the open-label treatment phase),\n                      <jats:italic>long-term persistent reversion<\/jats:italic>\n                      to episodic migraine over 64 weeks (double-blind treatment phase plus open-label treatment phase);\n                      <jats:italic>delayed reversion<\/jats:italic>\n                      to episodic migraine through the first 12 weeks of the open-label treatment phase among patients remaining in chronic migraine during the double-blind treatment phase.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the double-blind treatment phase, 53.1% (95% confidence interval: 47.8\u201358.3) of 358 erenumab-treated completers had reversion to episodic migraine; monthly reversion rates to episodic migraine were typically higher among patients receiving 140\u2009mg versus 70\u2009mg. Among 181 completers (receiving erenumab for 64 weeks), 98 (54.1% [95% confidence interval: 46.6\u201361.6]) had reversion to episodic migraine during the double-blind treatment phase; of those, 96.9% (95% confidence interval: 91.3\u201399.4) had persistent reversion to episodic migraine, 96.8% (95% confidence interval: 91.1\u201399.3) of whom had long-term persistent reversion to episodic migraine. Delayed reversion to episodic migraine occurred in 36\/83 (43.4% [95% confidence interval: 32.5\u201354.7]) patients; of these, 77.8% (95% confidence interval: 60.9\u201389.9) persisted in reversion through week 64.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with reversion to episodic migraine at week 12 will likely persist as episodic migraine with longer-term erenumab; others may achieve delayed reversion to episodic migraine.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Clinical trial registration:<\/jats:bold>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      . Unique identifier: NCT02066415\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0333102420973994","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T10:16:06Z","timestamp":1606990566000},"page":"6-16","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":29,"title":["Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a\n                    <i>post-hoc<\/i>\n                    analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension"],"prefix":"10.1177","volume":"41","author":[{"given":"Richard B","family":"Lipton","sequence":"first","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J","family":"Tepper","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth, Hanover, NH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-5567","authenticated-orcid":false,"given":"Stephen D","family":"Silberstein","sequence":"additional","affiliation":[{"name":"Jefferson Headache Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kudrow","sequence":"additional","affiliation":[{"name":"California Medical Clinic for Headache, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[{"name":"Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Dodick","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Rippon","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[{"name":"Global Development, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Mikol","sequence":"additional","affiliation":[{"name":"Global Development, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000323925.29520.e7"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-012-0460-7"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12755"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000113747.18760.D2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d8af2"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004177"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417699180"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_3_4_17_2","volume-title":"Aimovig (package insert)","author":"Amgen Inc","year":"2018","unstructured":"Amgen Inc. Aimovig (package insert). Thousand Oaks, CA: Amgen Inc., 2018."},{"key":"e_1_3_4_18_2","volume-title":"Summary of product characteristics","author":"Aimovig (erenumab)","year":"2018","unstructured":"Aimovig (erenumab). Summary of product characteristics. Dublin, Ireland: Novartis Europharm Ltd, 2018."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13652"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00655"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307149"},{"key":"e_1_3_4_25_2","unstructured":"Lipton RB Cohen JM Yang R et\u00a0al. Long-term efficacy of fremanezumab in patients who reverted from a chronic to an episodic migraine classification. Headache 2019; 59(Suppl1): 101\u2013102."},{"key":"e_1_3_4_26_2","unstructured":"Hindiyeh NA Detke HC Day K et\u00a0al. Shift from chronic migraine to episodic migraine status in a long-term phase 3 study of galcanezumab. Headache 2019; 59(Suppl1): 103."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1215"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01555.x"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004391"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102420973994","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0333102420973994","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102420973994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:48:58Z","timestamp":1777387738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0333102420973994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/0333102420973994"],"URL":"https:\/\/doi.org\/10.1177\/0333102420973994","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}